Registered Nurse in Wittmann, AZ Accepting Medicare
4 Registered Nurse nurses found. Showing 1 - 4
 Christine Florendo, RN Registered Nurse - School Medicare: Not Enrolled in Medicare Practice Location: 21419 W Dove Valley Rd, Wittmann, AZ 85361 Phone: 623-388-2321 Fax: 623-388-2204 |
Dana Marie Cannella, Registered Nurse - Lactation Consultant Medicare: Not Enrolled in Medicare Practice Location: 32512 N 225th Dr, Wittmann, AZ 85361 Phone: 845-216-5299 |
Jo Ann Durnall, Registered Nurse - School Medicare: Not Enrolled in Medicare Practice Location: 21419 W Dove Valley Rd, Wittmann, AZ 85361 Phone: 623-388-2126 Fax: 623-388-2204 |
Mrs. Shari Lynn Molera, RN Registered Nurse - School Medicare: Not Enrolled in Medicare Practice Location: 32919 W Center St, Wittmann, AZ 85361 Phone: 623-388-2321 |
News Archive
Study: Patients with community-acquired pneumonia who develop AKI more likely to die after discharge
Patients hospitalized with even mild to moderate community-acquired pneumonia who develop acute kidney injury (AKI) are more likely to die after discharge than pneumonia patients whose kidneys remain healthy, according to a University of Pittsburgh School of Medicine study in the February issue of Kidney International.
Researchers use heavy and non-heavy drinking levels to evaluate effectiveness of alcohol treatment
One of the challenges in evaluating the effectiveness of alcohol treatment is determining what constitutes a "good" outcome or meaningful improvement. While abstinence at the end of treatment is clearly a good outcome, a focus on abstinence ignores the benefits of patients reducing their drinking to less problematic levels so that they can function better and incur fewer social costs.
New CT scanner offers quality diagnostic images and emits minimum radiation
NYU Langone Medical Center is the first hospital in the Northeast to offer one of the world's fastest and most radiation dose efficient computed tomography (CT) scanner.
Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations
In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.
European scientists discuss strategies to strengthen the role of EU in promoting global public health
Taken together, the EU's member states constitute the world's largest aid donor to the low and middle-income countries, and the largest trade zone. This puts the EU in a unique position to contribute to better global health. But first, its member states must decide on their goals and how they can work together to achieve them.
› Verified 1 days ago